Public Health and Prevention
- Cost Estimate
S. 272, Protect Infant Formula from Contamination Act
As reported by the Senate Committee on Health, Education, Labor, and Pensions on January 28, 2026
- Report
The Opioid Crisis: Federal Policy Approaches to Reduce Supply, Demand, and Harm
CBO describes three types of policy approaches to address the ongoing opioid crisis and assesses their effectiveness and likely budgetary effects.
- Cost Estimate
H.R. 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act
As passed by the House of Representatives on June 23, 2025
- Report
Growth in the 340B Drug Pricing Program
CBO examines drug purchases made through the 340B program in 2021, growth in such purchases from 2010 to 2021, and factors that contributed to that growth. CBO also assesses how the 340B program affects the federal budget.
- Cost Estimate
S. 632, IHS Workforce Parity Act of 2025
As reported by the Senate Committee on Indian Affairs on May 12, 2025
- Cost Estimate
S. 289, Youth Poisoning Protection Act
As ordered reported by the Senate Committee on Commerce, Science, and Transportation on March 12, 2025
- Cost Estimate
S. 389, Setting Consumer Standards for Lithium-Ion Batteries Act
As ordered reported by the Senate Committee on Commerce, Science, and Transportation on March 12, 2025
- Cost Estimate
S. 414, ADS for Mental Health Services Act
As reported by the Senate Committee on Commerce, Science, and Transportation on June 24, 2025
- Cost Estimate
H.R. 1442, Youth Poisoning Protection Act
As passed by the House of Representatives on April 29, 2025
- Presentation
The Federal Perspective on Coverage of Medications to Treat Obesity: Considerations From the Congressional Budget Office
Presentation by Noelia Duchovny, an analyst in CBO’s Health Analysis Division, at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop on GLP-1-Based Therapies.